✦ LIBER ✦

Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

✍ Scribed by F. Backes; D. Richardson; G. McCann; R. Salani; E. Eisenhauer; J. Fowler; L. Copeland; D. Cohn; D. O'Malley

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Should bevacizumab be continued beyond p

✍ Axel Grothey; Dirk Arnold; Lee M. Ellis 📂 Article 📅 2008 🏛 Current Science Inc. 🌐 English ⚖ 200 KB

Sustained progression-free survival with

✍ J.D. Hurt; D.L. Richardson; L.G. Seamon; J.F. Fowler; L.J. Copeland; D.E. Cohn; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 233 KB

Downstream effects of first line bevaciz

✍ E. Bishop; L. Perry; R. Previs; A. Alvarez-Secord; K. Moore 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Bladder perforation in a patient with re

✍ Nisha Bansal; Mitchell Hoffman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Which factors predict bowel complication

✍ D.L. Richardson; F.J. Backes; J.D. Hurt; L.G. Seamon; L.J. Copeland; J.M. Fowler 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Addition of bevacizumab to weekly paclit

✍ David M. O'Malley; Debra L. Richardson; Patrick S. Rheaume; Ritu Salani; Eric L. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 249 KB